Published On: Wed, Oct 19th, 2016

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) Analyst Review


A number of investment brokers have recently updated their price targets on shares of Isis Pharmaceuticals, Inc. (NASDAQ:ISIS).

Most recent broker ratings

12/18/2015 – Isis Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Piper Jaffray.

12/03/2015 – Wells Fargo began new coverage on Isis Pharmaceuticals, Inc. giving the company a “outperform” rating.

11/18/2015 – Goldman Sachs began new coverage on Isis Pharmaceuticals, Inc. giving the company a “neutral” rating. They now have a USD 65 price target on the stock.

11/10/2015 – Isis Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 88 price target on the stock.

11/09/2015 – Isis Pharmaceuticals, Inc. had its “equal weight” rating reiterated by analysts at Barclays. They now have a USD 65 price target on the stock.

06/22/2015 – Isis Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 78 price target on the stock.

06/11/2015 – Isis Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 95 price target on the stock.

06/08/2015 – Isis Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at JP Morgan. They now have a USD 68 price target on the stock.

05/08/2015 – Isis Pharmaceuticals, Inc. was upgraded to “buy” by analysts at Zacks. They now have a USD 68 price target on the stock.

04/20/2015 – Isis Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Cowen.

03/17/2015 – Janney Montgomery Scott began new coverage on Isis Pharmaceuticals, Inc. giving the company a “neutral” rating.

03/02/2015 – Isis Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Brean Capital.

03/02/2015 – Isis Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Stifel Nicolaus. They now have a USD 66 price target on the stock.

01/20/2015 – Isis Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 68 price target on the stock.

12/08/2014 – Isis Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Laidlaw. They now have a USD 65 price target on the stock.

The share price of Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) was up +0.00% during the last day of trading, with a day high of 0.00. 0 shares were traded during the last session.

The stock’s 50 day moving average is 58.93 and its 200 day moving average is 53.82.Isis Pharmaceuticals, Inc. has a 52-week low of 37.38 and a 52-week high of 77.80.

Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.